Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

IDENTIFIER (ClinicalTrials.gov): NCT06788938

DRUG/TREATMENT: Tarlatamab

PHASE: 2

STATUS: Recruiting

SPONSOR: Jonsson Comprehensive Cancer Center

DESCRIPTION:

This is a Phase II, multi-center “basket” study testing a medication called tarlatamab in people with advanced cancers that show a marker called DLL3. DLL3 is a protein found on the surface of some neuroendocrine and other hard-to-treat tumors.

What is Tarlatamab?

Tarlatamab is an anti-cancer therapy that helps the immune system find and attack cancer cells. It is already FDA-approved for extensive-stage small cell lung cancer, but its use in other tumors is still considered investigational, meaning researchers are studying how well it works and how safe it is for these additional cancer types.

About the Study

This trial is being done to learn:

• How well tarlatamab works in treating DLL3-positive cancers

• What side effects it may cause

• How safe and tolerable the treatment is in different types of tumors

  
  

The study is enrolling people with advanced DLL3-expressing tumors other than small cell lung cancer or neuroendocrine prostate cancer.

Participants will receive tarlatamab as long as it is helping and side effects remain manageable. Treatment will continue until the cancer grows, side effects become unacceptable, the patient chooses to stop, or another medical reason requires stopping.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT

Contact: CRU Hotline

Phone Number: 888-798-0719

Email: istteam@mednet.ucla.edu

Study Contact Backup

Name: CRU Direct line

Phone Number: 310-206-2632

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.